Laurie A. LeBrun

机构：Eli Lilly (United States)

发表论文 46 篇 · 总被引 1796 次 · h-index 23

代表论文

• A Cereblon Modulator (CC-220) with Improved Degradation of Ikaros and Aiolos (2017 · Journal of Medicinal Chemistry · 被引 307)
• Discovery of CRBN E3 Ligase Modulator CC-92480 for the Treatment of Relapsed and Refractory Multiple Myeloma (2020 · Journal of Medicinal Chemistry · 被引 232)
• CC-90009: A Cereblon E3 Ligase Modulating Drug That Promotes Selective Degradation of GSPT1 for the Treatment of Acute Myeloid Leukemia (2021 · Journal of Medicinal Chemistry · 被引 156)
• Interaction of the N-Terminal Domain of Apolipoprotein E4 with Heparin (2001 · Biochemistry · 被引 101)
• Protein Degradation via CRL4CRBN Ubiquitin Ligase: Discovery and Structure–Activity Relationships of Novel Glutarimide Analogs That Promote Degradation of Aiolos and/or GSPT1 (2017 · Journal of Medicinal Chemistry · 被引 78)
• Direct Measurement of the Interactions of Glycosaminoglycans and a Heparin Decasaccharide with the Malaria Circumsporozoite Protein (2001 · Biochemistry · 被引 68)